ag-Ip-news

The Only Specialized Global Intellectual Property News Agency
A Member of Talal Abu-Ghazaleh Organization
Arabic
Advanced Search
Mailing List Sign Up
Enter your e-mail address to receive daily headlines.

Unsubscribe
Click here for World Law news from NewsNow.co.uk
WAP Service


AGIPNEWS2443

19/3/2005 07:34 GMT
ag-IP-news
Alizyme Acquires Patent and IPRs to Colal Drug Delivery Technology

CAMBRIDGE - Alizyme plc announced on Saturday that it has acquired the intellectual property rights (IPRs), including patents and know-how, to the COLAL colonic drug delivery technology owned by BTG plc.

According to a press release by the Company, COLAL is a drug delivery technology which enables drugs to be taken orally and then be specifically released when the preparation reaches the colon.

The technology is currently being exploited in the development of COLAL-PRED, Alizyme's novel product for the treatment of ulcerative colitis, which recently received approval for a pivotal Phase III clinical trial in Europe.

The patents are currently granted in the major commercial territories, including the USA and Europe and were previously licensed from BTG under an exclusive worldwide license.

This new agreement, assigning these worldwide rights, will allow Alizyme to maximize the future commercial return from exploiting this unique technology with its current product COLAL-PRED and with other potential products in the future.

In respect of those patents that relate to the COLAL drug delivery technology that cover Alizyme's COLAL-PRED product, the terms of the deal provide that Alizyme pays £750,000 on signature of the agreement and a further £550,000 on recording the assignments at the appropriate patent offices. Alizyme will take outright ownership of these patents, with no further amounts being payable.

In respect of the other assigned patent families, which relate to other aspects of colonic drug delivery technology, Alizyme will pay a total of £75,000 over the next three years, royalties on any sales of relevant products and a share of any other consideration received by Alizyme for exploitation of these patents. Alizyme will look to identify new potential product opportunities in conjunction with this drug delivery technology.


Related Articles
Court Issues Order Construing Disputed Terms in Neutral Tandem Patent Infringement Case
Sybase Continues to Assert Vertica’s Infringement of Sybase Patents
Appeals Court Affirms Patent Infringement Rulings Against Emptoris
Palomar's Patent Infringement Lawsuits Against Candela and Syneron Reopened
Nokia Requests ITC Investigation into Apple Patent Infringement
Infineon Reaches Agreement to Settle Legal Dispute with Fairchild
Retractable Technologies Announces Verdict in Patent Infringement Suit
Court Issues Ruling on Star Scientific Motion for Judgment as a Matter of Law
Hologic Announces Decision in Patent Infringement Suit
SenoRx Found Not Liable for Patent Infringement

Top
Go

Home | About Us | How to Use Our Services | Links | Download Our News Ticker | FAQ | What is IP? | Contact Us
Copyright © 2008 ag-IP-news All Rights Reserved
Disclaimer   Terms of Use    Privacy Policy